Australia's most trusted
source of pharma news
Posted 4 November 2025 AM
Eli Lilly's tirzepatide franchise, Zepbound and Mounjaro, blew the world’s bestselling drug, Keytruda, out of the water in Q3 2025, with the company smashing expectations and reasserting its dominance in the GLP-1 market.
The mega blockbuster weight loss and diabetes drugs brought in combined worldwide revenue of US$10.1 billion in the third quarter, up from US$4.4 billion in Q3 2024, Lilly reported last week. Cancer drug Keytruda, in comparison, earned US$8.1 billion for MSD.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.